Overview

Efficacy and Safety Evaluation of IBI188 in Combination With Azacitidine in Treatment of Patients With Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The study is to evaluate safety， tolerability and composite CR of IBI188 plus azacitidine in acute myeloid leukemia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Azacitidine